SCHEMBL7062972

SCHEMBL7062972

CC(C)CC(NS(=O)(=O)c1cccs1)C(=O)O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 1/20 0.56
SLC1A2 P43004 1/20 0.56
SLC1A1 P43005 1/20 0.56
ALDH1A1 P00352 5/20 0.54
CYP2C19 P33261 1/20 0.52
MMP1 P03956 1/20 0.52
MMP2 P08253 1/20 0.52
MMP3 P08254 1/20 0.52
MMP7 P09237 1/20 0.52
MMP9 P14780 1/20 0.52
MMP13 P45452 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.51
TSHR P16473 2/20 0.51
HTT P42858 1/20 0.51
MAPT P10636 2/20 0.49
KDM4E B2RXH2 2/20 0.49
TP53 P04637 3/20 0.48
ADAM17 P78536 1/20 0.48
THRB P10828 1/20 0.48
MEN1 O00255 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6589504 0.82 SLC1A3 (0.54) SLC1A3SLC1A2SLC1A1ALDH1A1CYP2C19
SCHEMBL30856551 0.81 SLC1A3 (0.62) SLC1A3SLC1A2SLC1A1ALDH1A1CYP2C19
SCHEMBL2735619 0.81 TSHR (0.70) SLC1A3SLC1A2SLC1A1ALDH1A1MMP2
SCHEMBL6561338 0.78 MMP2 (0.70) ALDH1A1CYP2C19MMP1MMP2MMP3
SCHEMBL15251807 0.78 MMP2 (0.70) ALDH1A1CYP2C19MMP1MMP2MMP3
SCHEMBL5191083 0.78 MMP2 (0.70) ALDH1A1CYP2C19MMP1MMP2MMP3
SCHEMBL7062243 0.77 KDM4E (0.54) ALDH1A1CYP2C19MMP1MMP2MMP3
SCHEMBL7061397 0.76 MMP2 (0.51) ALDH1A1CYP2C19MMP1MMP2MMP3
Trifluoroacetic Acid SCHEMBL7654076 0.76 SLC1A3 (0.54) SLC1A3SLC1A2SLC1A1ALDH1A1CYP2C19
SCHEMBL7060922 0.76 MMP2 (0.48) ALDH1A1CYP2C19MMP1MMP2MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production THOMPSON LORIN A (US) 2003-07-10 US claimed
US-6503901-B1 Alzheimer*s disease and Down*s syndrome treatment BRISTOL MYERS SQUIBB PHARMA COMPANY 2003-01-07 US claimed
EP-1218377-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-03 EP claimed
WO-2001027108-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-04-19 WO claimed
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production THOMPSON LORIN A (US) 2003-07-10 US disclosed
US-6503901-B1 Alzheimer*s disease and Down*s syndrome treatment BRISTOL MYERS SQUIBB PHARMA COMPANY 2003-01-07 US disclosed
EP-1222176-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-17 EP disclosed
EP-1218377-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-03 EP disclosed
WO-2001027091-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION DU PONT PHARMACEUTICALS COMPANY (US) 2001-04-19 WO disclosed
WO-2001027108-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production APP, APH1A, BACE1 SLC1A3 397/4885SLC1A2 249/4885SLC1A1 453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.